Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
8.48
-1.08 (-11.30%)
At close: Oct 30, 2026, 4:00 PM EDT
8.45
-0.03 (-0.35%)
After-hours: Oct 30, 2026, 7:59 PM EDT
Iovance Biotherapeutics Employees
Iovance Biotherapeutics had 975 employees as of December 31, 2025. The number of employees increased by 137 or 16.35% compared to the previous year. That makes Iovance Biotherapeutics the 15,094th largest employer in the world and 2,192nd in the United States.
Employees
975
Change (1Y)
137
Growth (1Y)
16.35%
Revenue / Employee
$333,302
Profits / Employee
-$296,941
Market Cap
3.84B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 975 | 137 | 16.35% |
| Dec 31, 2024 | 838 | 281 | 50.45% |
| Dec 31, 2023 | 557 | 54 | 10.74% |
| Dec 31, 2022 | 503 | 184 | 57.68% |
| Dec 31, 2021 | 319 | 78 | 32.37% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Acadia Pharmaceuticals | 798 |
| AbCellera Biologics | 562 |
| Xenon Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| Relay Therapeutics | 202 |
| Disc Medicine | 165 |
| Parabilis Medicines | 145 |
IOVA News
- 1 day ago - Iovance price target lowered to $9 from $11 at Baird - TheFly
- 2 days ago - Iovance falls -35.4% - TheFly
- 2 days ago - Iovance falls -25.1% - TheFly
- 2 days ago - Iovance reports updated IOV-LUN-202 results for lifileucel in lung cancer - TheFly
- 2 days ago - Iovance Biotherapeutics Transcript: Study update - Transcripts
- 2 days ago - Iovance Biotherapeutics Slides: Study update - Filings
- 2 days ago - Iovance Biotherapeutics Press release: Study update - Filings
- 2 days ago - Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC) - GlobeNewsWire